Compare Dover Corp (DOV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Smith & Nephew plc — how do they compare? Dover Corp trades at $189.35 (market cap $25.45B), while Smith & Nephew plc trades at $27.1 (market cap $11.10B). The key difference: Dover Corp is far larger — about 2.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Smith & Nephew plc for 120 Days on average.
| DOV | SNN | |
|---|---|---|
Market Cap | $25.45B | $11.10B |
Volume | 661,758 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $233.31 | $37.17 |
52-Week Low | $161.16 | $26.42 |
Typical Hold Time | 73 Days | 120 Days |
Enterprise Value | $26.95B | $14.13B |
Dividend Yield | 1.11% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $189.32, up 0.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 results pending. Revenue for 2025 was $8.09B, with a net income margin of 13.48%, while analyst consensus is strongly positive with a $243.20 price target. Recent news highlights product launches and strategic acquisitions, such as the completion of the Cloeren acquisition in August 2026.
DOV presents a favorable fundamental outlook with solid profitability and analyst support, though technical indicators suggest near-term caution. Upside potential exists from earnings momentum and dividend reliability, but risks include market volatility and execution challenges from recent acquisitions. The stock's current price is below the consensus target, indicating room for growth if quarterly results meet expectations.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
